Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotech
Latest Price: 0.02  (-13.04% Descending)
52-week High: 0.09
52-week Low: 0.01
Market Cap: 34.31M
1 year chart
1 day chart
Genetic Technologies
Genetic Technologies (ASX: GTG, NASDAQ Capital Market: GENE) is leading-edge genetic testing  business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA on health.

Genetic Technologies’ breast cancer test gets clearance for sale in Florida, shares rally

25th Sep 2012, 11:25 am by Carrie White
Genetic Technologies says its breast cancer test has been cleared for sale in Florida, sending its shares higher. Genetic Technologies says its breast cancer test has been cleared for sale in Florida, sending its shares higher.


Genetic Technologies (ASX:GTG) (NASDAQ:GENE) saw its shares soar over 19 per cent Tuesday, after it announced that its breast cancer test BREVAGen has been cleared for sale in Florida.

Shares of the company were ahead 19.58 per cent as at about 11:30 a.m. ET, trading at $4.01.

Genetic’s BREVAGen breast cancer risk stratification test examines a patient's DNA to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer. 

The company said the test is designed to help physicians assess breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient's family and personal history, thus giving a clearer picture of an individual woman's risk of developing the disease. 

Genetic said that the clearance came following the grant of a permit to the company’s Australian-based laboratory by the Florida Agency for Healthcare Administration (AHCA).

In July, the company said it received clearance of BREVAGen for sale into California. 

“Combined, Florida and California represent between 15 and 20 per cent of breast cancer incidence in the U.S.,” the company said in a statement Tuesday.

Genetic said that a regional business manager has already been trained and put into place in Florida by the company’s U.S. subsidiary, Phenogen Sciences Inc. 

Having pre-qualified several key accounts in the territory already, the company said it expects to immediately start sales in the region. 

Genetic has successfully attained approval allowing BREVAGen to be sold into 42 U.S. States. It said it has also has submitted numerous applications for "out of state licensure”, which allows BREVAGen to now also be sold in Pennsylvania, Rhode Island, Nevada, Tennessee, Maryland, California and Florida.

The company has submitted an application along with supporting test documentation to the New York State Department of Health, to offer out of state clinical lab services to New York State residents. 

Genetic said that the application is under review, and once New York State approval is granted, the BREVAGen test will have been cleared for sale in all 50 U.S. States.

The company said the test may be “especially useful” for women predisposed to hormone dependant breast cancer, including those who have undergone breast biopsies.

The test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a personalized patient-by-patient basis. 

Genetic Technologies is a diagnostics company focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. 

Its U.S. subsidiary, Phenogen Sciences, offers predictive testing and assessment tools to help physicians proactively manage women's health. 


No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here